Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Effectiviteit en immunogeniciteit van het R21/Matrix-M-vaccin: 2 jaar follow-up
feb 2023 | Parasitaire infecties